FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer

FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer

Top 10 OncoGrants of the Week: Funding Translation, Implementation, and Oncology Capacity

OncoGrants

Oncology This Week: OncoDaily Weekly Dec 8–14, 2025

OncoDaily Weekly

Candle Lighting Day: A Global Moment of Remembrance and Solidarity 2025

Candle Lighting Day: A Global Moment of Remembrance and Solidarity 2025

ASCO Announces Featured Voices of the Gastrointestinal Cancers Symposium 2026

ASCO

Alessandro Gronchi: Two Decades of Progress in Retroperitoneal Sarcoma Outcomes

Alessandro Gronchi

Bishal Gyawali: Why De-Escalation Trials Can Be Designed as Superiority Instead of Non-Inferiority

Bishal Gyawali, De-Escalation Trials

10 Oncology Experts Join OncoDaily Medical Journal's Editorial Team

OncoDaily Medical Journal

Sharon Dent